Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02238184
Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8135
- Registration Number
- NCT02238275
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Phase 3
Completed
- Conditions
- Secondary PreventionStroke
- Interventions
- Drug: placebo to optional ASA as comedication
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5390
- Registration Number
- NCT02239120
- Locations
- 🇩🇪
Klinikum Coburg gGmbH, Coburg, Germany
🇩🇪Klinikzentrum Mitte, Dortmund, Dortmund, Germany
🇩🇪Klinikum Hanau GmbH, Hanau, Germany
Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 660
- Registration Number
- NCT02238145
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2318
- Registration Number
- NCT02238262
Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Alesion®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2001
- Registration Number
- NCT02238223
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)Drug: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT02238314
Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02238119
Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus
Completed
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- Drug: Alesion®
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3793
- Registration Number
- NCT02238236
Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 230
- Registration Number
- NCT02238210
© Copyright 2025. All Rights Reserved by MedPath